Recker, Pia http://orcid.org/0000-0002-0337-9613
Beck, Bodo Bernhard http://orcid.org/0000-0003-0495-7670
Sikora, Przemyslaw http://orcid.org/0000-0002-5698-6863
Göbel, Heike http://orcid.org/0000-0002-0171-7025
Kemper, Markus Josef http://orcid.org/0000-0002-9205-7906
Nazco, Angel http://orcid.org/0000-0001-6685-7267
Martin-Higueras, Cristina http://orcid.org/0000-0003-1139-4642
Hoppe, Bernd http://orcid.org/0000-0002-8120-3306
Funding for this research was provided by:
Horizon 2020 Framework Programme (643578)
Ministerio de Ciencia e Innovación (FJC2018-036199-I)
Deutsche Forschungsgemeinschaft (SFB/TRR 57)
Universitätsklinikum Köln
Article History
Received: 25 March 2022
Accepted: 31 August 2022
First Online: 6 October 2022
Competing interests
: CMH is a consultant of Dicerna a NovoNordisk subsidiary, USA/Denmark. BBB received consulting fees from Alnylam Pharmaceuticals, USA. BH has been an employee of Dicerna a NovoNordisk subsidiary, USA/Denmark. The other authors have nothing to declare.